Hims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for Canadians

Hims & Hers Health, Inc. today announced the completion of its acquisition of Eucalyptus, the parent company of Juniper, marking the latest in a series of significant company investments in Canada. Since launching in 2025, Hims & Hers has already changed the game in Canada, becoming the first platform to bring generic semaglutide to eligible Canadians. By combining Juniper's proven platform with the technology, data, and clinical infrastructure that has advanced Hims & Hers’ position as the world's largest consumer health platform, more Canadians can benefit from preventive, whole-body care than ever before.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602648634/en/

Building on its Canadian launch and the historic introduction of generic semaglutide, Hims & Hers brings the full power of the world's largest consumer health platform — and Juniper's proven track record — to more Canadians than ever

In a country where nearly two thirds of adults are overweight or living with obesity, the need for accessible, personalised weight management care has never been greater. Juniper has built one of the most trusted weight management programs in the markets it serves, pairing personalised treatment with consistent, high-touch clinical support. This expanded platform will allow Hims & Hers to delve into additional areas of care where Canadians have historically lacked access, including sexual health, and hair loss, building a platform that supports health across every adult stage of life.

Canada's healthcare system delivers strong foundational care, but meaningful gaps remain around prescription affordability, chronic disease management, and preventive health. Hims & Hers is committed to closing those gaps, helping Canadians access personalised, preventive care before conditions escalate, reducing long-term health burdens and helping people live longer, healthier lives.

"From being first to market with generic semaglutide to completing this acquisition, every step for Hims & Hers in Canada has been guided by that same purpose: expanding access to the care Canadians need, when they need it," said Andrew Dudum, co-founder and CEO of Hims & Hers. "We are committed to helping Canadians live fuller, more vibrant lives by building something different — preventive, personalised care that’s built around how people actually live."

Schreibe Deinen Kommentar